Navitoclax is an N-sulfonylcarboxamide formed by the condensation of the carboxy group of 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}benzoic acid with the amino group of 4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide. It is a BH3-mimetic drug that targets anti-apoptotic BCL-2 family proteins, including BCL-2, BCL-xL, and BCL-w, inducing apoptosis in cancer cells. Currently under clinical investigation for solid tumors and hematologic malignancies. It functions as a BCL-2 inhibitor, apoptosis inducer, and antineoplastic agent. It belongs to piperazines, monochlorobenzenes, morpholines, aryl sulfides, N-sulfonylcarboxamides, sulfones, organofluorine compounds, secondary amino compounds, and tertiary amino compounds.
